<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred forty-seven patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> and treated by allogeneic marrow transplants received <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prevention with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, 73 of the 147 patients were randomized to receive <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> during the first 35 days after transplant to improve GVHD prevention, whereas 74 patients were randomized not to receive <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The randomized trial enabled us to examine whether <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> increased the risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> after marrow grafting </plain></SENT>
<SENT sid="3" pm="."><plain>Charts of study patients were analyzed retrospectively for <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> events including <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremia</z:e>, <z:mpath ids='MPATH_681'>septicemia</z:mpath>, and <z:e sem="disease" ids="C0085082" disease_type="Disease or Syndrome" abbrv="">fungemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The randomization was stratified by diagnosis, patient age, genotypic HLA identity, and assignment to laminar airflow room isolation </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were given a short course of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (no longer than 11 days) and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> for no longer than 180 days after marrow transplantation </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="6888">Methylprednisolone</z:chebi> was begun on the day of marrow grafting at a dose of 1 mg/kg body weight intravenously in divided AM and PM doses through day 22 </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6888">Methylprednisolone</z:chebi> was administered at a dose of 0.5 mg/kg in divided doses from days 22 through 35, and then discontinued </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> were analyzed for the time interval ending on day 65 after transplantation, which included the period of <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> administration and 1 month thereafter </plain></SENT>
<SENT sid="9" pm="."><plain>Seventy-one episodes of first <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> events were observed in patients receiving <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> compared with 47 episodes in patients not receiving the drug </plain></SENT>
<SENT sid="10" pm="."><plain>Predominant <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteremias</z:e>, followed in descending order by <z:e sem="disease" ids="C0085082" disease_type="Disease or Syndrome" abbrv="">fungemias</z:e> and <z:mpath ids='MPATH_681'>septicemias</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>The most prevalent organisms cultured were <z:mp ids='MP_0001796'>gram-positive</z:mp> bacteria, especially coagulase-negative Staphylococcus and Streptococcus species </plain></SENT>
<SENT sid="12" pm="."><plain>Pseudomonas species were the most common <z:mp ids='MP_0001795'>gram negative</z:mp> bacteria, and the most prevalent fungus was Candida albicans </plain></SENT>
<SENT sid="13" pm="."><plain>Multivariable Cox regression analysis showed that patients receiving <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> had a 1.5 times higher risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (P = .03), with <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD being another independent risk factor for <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (P = .005) </plain></SENT>
<SENT sid="14" pm="."><plain><z:chebi fb="0" ids="6888">Methylprednisolone</z:chebi>, when added to GVHD prevention by <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>, increases the risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> during the early posttransplantation period </plain></SENT>
</text></document>